<DOC>
	<DOCNO>NCT00564629</DOCNO>
	<brief_summary>To assess rapidity onset antipyretic effect efficacy safety single dose IV acetaminophen ( IV APAP ) versus oral ( PO ) acetaminophen treatment fever induce standard dose endotoxin</brief_summary>
	<brief_title>Study Efficacy Safety Intravenous v Oral Acetaminophen Treatment Fever Healthy Adult Males</brief_title>
	<detailed_description>A Phase III , Randomized , Double-Blind , Double-Dummy , Single-Dose Study Efficacy Safety Intravenous Acetaminophen Versus Oral Acetaminophen Treatment Endotoxin-Induced Fever Healthy Adult Males</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Inclusion Criteria ( Screening ) To eligible entry Study , Subjects must meet follow criterion Screening : Provide write Informed Consent prior participation Study Be healthy male age 18 75 year age , inclusive , Randomization Have Body Mass Index ( BMI ) ≥ 19 ≤ 45 lbs/in2 Have ability read understand Study procedure ability communicate meaningfully Study Investigator staff Be free physical , mental , medical condition , opinion Investigator , may confound quantify assessment Study Be willing abstain smoking cigarette use nicotine product time admission Clinic Study Completion Inclusion Criteria ( PreRandomization ) To eligible Randomization , Subjects must meet following criterion : Be free evidence infection base upon clinical assessment blood ( Complete Blood Count CBC ) urine test Have average baseline oral temperature equal 37 ºC ( 98.6 ºF ) vary 0.4 ºC ( 0.7 ºF ) low high three assessment perform 30minute period Not develop medically significant allergic exaggerate systemic response administration test dose reference standard endotoxin Develop core temperature least 38.6 ºC ( 101.5 ºF ) IV reference standard endotoxin dose per Study guideline fever response endotoxin near peak temperature virtue two consecutive temperature assessment 5 minute apart within 0.2 ºC ( 0.4 ºF ) Has treat medication antipyretic effect ( e.g. , corticosteroid , nonsteroidal antiinflammatory drug [ NSAID ] , aspirin , acetaminophen ) within 2 day clinic admission ( aspirin low dose cardiac prophylaxis allow , take day Study ) Has significant medical disease ( ) , laboratory abnormality , condition ( ) Investigator 's judgment could compromise Subject 's welfare , ability communicate Study staff , complete Study activity , would otherwise contraindicate Study participation Has know hypersensitivity contraindication receive endotoxin Investigator 's clinical judgment merit discontinuation Study participation Has know hypersensitivity acetaminophen , inactive ingredient ( excipients ) intravenous ( IV ) oral ( PO ) acetaminophen formulation Rescue Medications ( ibuprofen , aspirin , ketorolac ) Has know suspect recent history alcohol drug abuse dependence define Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criterion Has history nasal polyp , angioedema , significant actively treat bronchospastic disease , significant medical condition contraindicates participation Study receive endotoxin , Study Medication , Rescue Medication Has active infection disease condition may cause abnormal alteration body temperature Has impair liver function , e.g.Alanine aminotransferase ( ALT ) great equal 3 time upper limit normal , bilirubin great 3.0 , active hepatic disease , evidence clinically significant liver disease ( e.g. , cirrhosis hepatitis ) Has participate another clinical Study ( investigational market product ) within 30 day Screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>